Currently in shortage
Global precursor chemical restrictions affecting manufacture of amphetamine-class medicines. All strengths of Vyvanse experiencing reduced supply.
Expected resolution: 31 December 2025
lisdexamfetamine dimesylate
Vyvanse
70 mg · capsule · ADHD
PBS Pricing
| General patient co-payment | $31.60 |
| Concession co-payment | $7.70 |
| Full dispensed price | $78.60 |
PBS Information
- Item code
- ADHx03
- Drug name
- lisdexamfetamine dimesylate
- Brand name
- Vyvanse
- Manufacturer
- Takeda
- Formulation
- capsule
- Strength
- 70 mg
- Max quantity
- 30 units
- Max repeats
- 0
- PBS listed
- Yes
- Therapeutic group
- ADHD
TGA Reference: TGA-MSI-2025-011 · Sponsor: Takeda Pharmaceuticals Australia Pty Ltd
MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.